NCT06153329View on ClinicalTrials.gov

A Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of THDB0206 Injection in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 17, 2021

Primary Completion Date

June 6, 2022

Study Completion Date

June 6, 2022

Conditions
Healthy
Interventions
DRUG

THDB0206 injection

0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall

DRUG

Humalog®

0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall

DRUG

BC222insulin lispro injection

0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall

Trial Locations (1)

Unknown

West China Hospital of Sichuan University, Sichuan

All Listed Sponsors
lead

Tonghua Dongbao Pharmaceutical Co.,Ltd

INDUSTRY